Table 1 Baseline characteristics of patients at the initiation of systemic chemotherapy following duodenal stent placement
Characteristics | |
|---|---|
 Age (years), median (median) | 68.0 (31–81) |
Sex, n (%) | |
 Male | 54 (50) |
 Female | 55 (50) |
Primary disease, n (%) | |
 Pancreatic adenocarcinoma | 90 (83) |
 Biliary tract adenocarcinoma | 15 (14) |
 Pancreatic neuroendocrine neoplasms, Grade 2 | 3 (3) |
 Pancreatic neuroendocrine carcinoma | 1 (1) |
Disease status, n (%) | |
 Locally advanced | 24 (22) |
 Metastatic | 85 (78) |
ECOG* performance status | |
 0 | 18 (17) |
 1 | 62 (57) |
 2 | 29 (27) |
Position of bowel stricture, n (%) | |
 Oral side of the papilla of Vater | 33 (30) |
 Across the papilla of Vater | 26 (24) |
 Anal side of the papilla of Vater | 50 (46) |
Duodenal stent, n (%) | |
 WallFlex Duodenal | 46 (42) |
 WallFlex Duodenal Soft | 3 (3) |
 Niti-S D type | 46 (42) |
Niti-S COMVIâ„¢ | 4 (4) |
HANAROSTENT® Naturfit™ Duo | 10 (9) |
Number of chemotherapy regimens prior to duodenal stenting, n (%) | |
 0 | 47 (43) |
 1 | 49 (45) |
 2–3 | 13 (12) |
¶CRP (mg/dL), median (range) | 0.79 (0.05–12.9) |
Distribution, n (%) | |
  < 1.0 mg/dL | 60 (55) |
  ≥ 1.0 mg/dL | 49 (45) |
Albumin (g/dL), median (range) | 3.3 (2.1–4.1) |
Distribution, n (%) | |
  < 3.5 mg/dL | 67 (62) |
  ≥ 3.5 mg/dL | 42 (39) |
#CA19–9 (U/mL), median (range) | 928.9 (0–408,800.0) |
Distribution, n (%) | |
  < 1000 U/mL | 55 (50) |
  ≥ 1000 U/mL | 54 (50) |